<unk>  (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2). , it is in phase III clinical trials for the treatment of asthma. On Monday, December 16, 2019, Switzerland-based Novartis officially announced that it was jettisoning<unk>  from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped<unk>  would be a billion-dollar-selling asthma drug.
Fevipiprant
Estropipate
Elixir
Protandim
Snoezelen
Ripretinib
Abametapir
Progabide